Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorth Atl.smlr Regulatory News (NAS)

Share Price Information for North Atl.smlr (NAS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,050.00
Bid: 4,010.00
Ask: 4,040.00
Change: 0.00 (0.00%)
Spread: 30.00 (0.748%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 4,050.00
NAS Live PriceLast checked at -
North Atlantic Smaller Companies is an Investment Trust

To provide capital appreciation through investment in a portfolio of smaller companies principally based in countries bordering the North Atlantic Ocean.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

16 Sep 2021 16:22

RNS Number : 0600M
North Atlantic Smlr Co Inv Tst PLC
16 September 2021
 

North Atlantic Smaller Companies Investment Trust plc

Half-Yearly Report for the six months ended 31 July 2021

Registered in England and Wales number 1091347

 

objective of the company and financial highlights

North Atlantic Smaller Companies Investment Trust plc is a company incorporated and registered in England and Wales.

The objective of the Company is to provide capital appreciation through investment in a portfolio of smaller companies principally based in countries bordering the North Atlantic Ocean.

 

31 July

2021

(unaudited)

31 January

2021

(audited)

%

Change

Net asset value ("NAV") per 5p Ordinary Share*:

 

 

 

Basic and diluted

6,280p

5,292p

18.7

Basic and diluted adjusted#

6,285p

5,355p

17.4

Mid-market price of the 5p Ordinary Shares

4,800p

3,850p

24.7

Discount to net asset value

23.6%

27.2%

 

Discount to adjusted net asset value

23.6%

28.1%

 

Standard & Poor's 500 Composite Index†

3,162.3

2,709.5

16.7

Russell 2000 Index†

1,601.7

1,512.7

5.9

Ongoing charges (annualised)

1.1%

1.2%

 

 

* Includes current period.

# Adjusted to reflect Oryx International Growth Fund plc ("Oryx") under the equity method of accounting, which is how the Company previously accounted for its share of Oryx, prior to the adoption of IFRS 10. This is useful to the shareholder as it shows the NAV based on valuing Oryx at NAV. See note 6.

† Sterling adjusted.

 

 

chief executive's review

During the six month period under review, the net asset value rose by 17.4% (with Oryx under the equity method of accounting) as compared to a rise in the Sterling adjusted Standard & Poors Composite Index of 16.7%.

The Company incurred a revenue loss for the period of £874,000 (31 July 2020: loss of £629,000) as dividends remain depressed following the very severe economic disruption caused during the pandemic.

During the period, the Company purchased for cancellation 24,518 ordinary shares at a favourable discount to NAV which benefits all long term shareholders.

quoted portfolio

Stocks continued to rise sharply following the opening up of economies and a better than expected growth in GNP, particularly in the US and the UK. As a consequence, the performance of the UK quoted portfolio was most encouraging during the period.

Hargreaves Services and Assetco were the standout performers both rising by approximately 100%. Polar Capital rose 45%; Augean 30% following a bid; Sureserve 90% and Frenkel Topping 40%. Trellus went public with the stock now trading at a 200% premium to our book cost. Sadly, Esken continued to underperform due to virtually no passenger activity at Southend Airport. Source Bioscience also fell by circa 20% due to concerns over the future level of PCR testing.

It is also pleasing to note that both Oryx and Odyssean continued to outperform their benchmarks.

US portfolio

The portfolio is relatively small but performed satisfactorily during the period.

unquoted portfolio

The principal event during the period was the agreed offer for Hamsard/Pelsis. The price achieved was a significant premium to the end January valuation and will bring in excess of £20m of cash into the Company by end September 2021.

Coventbridge and three of our smaller holdings are also expected to be sold in the next twelve months creating uplifts and further cash returns to the Company.

outlook

As at 31 July 2021, the Company had cash and US Treasury bills of £72m. Following the sale of Augean/Pelsis this will increase significantly creating ample firepower for new investments. Of critical important will be for Renalytix to secure FDA approval for its proprietary test for kidney failure and then to present a credible story to investors as to how this unique technology can be commercialized.

In conclusion, the stock market has had an extraordinary recovery with many companies now trading on the concept of normalized earnings as the economic impact of COVID-19 subsides. Doubtless there are good opportunities but it is becoming harder to find equities which are fundamentally undervalued.

C H B Mills

Chief Executive

16 September 2021

top ten investments as at 31 July 2021

 

 

Fair

value

£'000

% of

net assets

Oryx International Growth Fund Limited *

UK Listed

136,023

15.5

EKF Diagnostics Holdings plc

UK Quoted on AIM

72,000

8.2

Renalytix AI plc

UK Quoted on AIM

67,481

7.7

US Treasury Bills

US Treasury Stock

61,476

7.0

Polar Capital Holdings plc

UK Quoted on AIM

60,720

6.9

Augean plc

UK Quoted on AIM

49,300

5.6

MJ Gleeson Group plc

UK Listed

41,200

4.7

Hargreaves Services Plc

UK Quoted on AIM

35,438

4.0

Harwood Private Equity Fund IV LP

UK Unquoted

33,259

3.8

Odyssean Investment Trust Plc

UK Listed

26,080

2.9

 

 

 

 

 

 

582,977

66.3

 

* Traded price under IFRS 10, incorporated in Guernsey.

All investments are valued at fair value.

 

interim management report

investment objective

The objective of North Atlantic Smaller Companies Investment Trust PLC is to provide capital appreciation to its shareholders through investing in a portfolio of smaller companies which are principally based in countries bordering the North Atlantic Ocean.

material events

The COVID-19 pandemic had a material impact on some of the Company's investments.

material transactions

There were no material transactions during the period.

risk profile

The principal risks and uncertainties for the remaining six months of the year continue to be as described in the Annual Report for the year ended 31 January 2021. The principal risks arising from the Company's financial instruments are market price risk, including currency risk, interest rate risk and other price risk, liquidity risk and credit risk. The Directors review and agree policies with the Manager, Harwood Capital LLP, for managing these risks. The policies have remained substantially unchanged in the six months since the year end.

The Company does not have any significant exposure to credit risk arising from any one individual party. Credit risk is spread across a number of counterparties, each having an immaterial effect on the Company's cash flows, should a default happen. The Company assesses the credit worthiness of its debtors from time to time to ensure that they are neither past due or impaired.

To support its investment in unquoted companies, the Company may periodically agree to guarantee all or part of the borrowings of investee companies. Provision is made for any costs that may be incurred when the Directors consider it likely that the guarantee will crystallise.

The Company's exposure to market price risk comprises mainly movements in the value of the Company's investments. It should be noted that the prices of options tend to be more volatile than the prices of the underlying securities. The Manager assesses the exposure to market risk when making each investment decision and monitors the overall level of market risk on the whole of the investment portfolio on an ongoing basis.

The functional and presentational currency of the Company is Sterling, and therefore, the Company's principal exposure to foreign currency risk comprises investments priced in other currencies, principally US Dollars.

The Company invests in equities and other investments that are realisable.

related party transactions

These are listed in note 9 to the half yearly condensed financial statements.

By Order of the Board

Peregrine Moncreiffe

Chairman

16 September 2021

 

responsibility statement

The Directors confirm to the best of their knowledge that:

· The condensed set of financial statements contained within this half yearly financial report have been prepared in accordance with International Accounting Standard ("IAS") 34 'Interim Financial Reporting' in conformity with the requirement of the Companies Act 2006 and gives a true and fair view of the assets, liabilities, financial position and profit of the Company; and

· The half yearly financial report includes a fair review of the information required by the FCA's Disclosure and Transparency Rule 4.2.7R being disclosure of important events that have occurred during the first six months of the financial year, their impact on the condensed set of financial statements and a description of the principal risks and uncertainties for the remaining six months of the year; and

· The half yearly financial report includes a fair review of the information required by the Disclosure and Transparency Rule 4.2.8R being disclosure of related party transactions during the first six months of the financial year, how they have materially affected the financial position of the Company during the period and any changes therein.

The half yearly financial report was approved by the Board on 16 September 2021 and the above responsibility statement was signed on its behalf by:

Peregrine Moncreiffe

Chairman

16 September 2021

 

condensed statement of comprehensive income (unaudited)

Six months ended31 July2021

Six months ended31 July2020

Year ended31 January2021

Revenue£'000

Capital£'000

Total£'000

Revenue£'000

Capital£'000

Total£'000

Revenue£'000

Capital£'000

Total£'000

Income

3,735

-

3,735

3,061

-

3,061

7,889

-

7,889

Net gains/(losses) on investments at fair value

-

138,958

138,958

-

(57,495)

(57,495)

-

133,879

133,879

Currency exchange losses

-

(140)

(140)

-

(136)

(136)

-

(563)

(563)

total income

3,735

138,818

142,553

3,061

(57,631)

(54,570)

7,889

133,316

141,205

Expenses

Investment management fee (note 9)

(3,755)

-

(3,755)

(3,190)

-

(3,190)

(6,380)

(3,769)

(10,149)

Other expenses

(842)

-

(842)

(482)

-

(482)

(963)

-

(963)

return before taxation

(862)

138,818

137,956

(611)

(57,631)

(58,242)

546

129,547

130,093

Taxation

(12)

-

(12)

(18)

-

(18)

(15)

-

(15)

return for the period

(874)

138,818

137,944

(629)

(57,631)

(58,260)

531

129,547

130,078

earnings per ordinary share (note 5)

Basic and diluted

985.2p

(411.4)p

920.3p

 

The total column of the statement is the Statement of Comprehensive Income of the Company prepared in accordance with International Financial Reporting Standards ("IFRS") in conformity with the requirement of the Companies Act 2006. The supplementary revenue and capital columns are presented for information purposes as recommended by the Statement of Recommended Practice ("SORP") issued by the Association of Investment Companies ("AIC").

All items in the above Statement derive from continuing operations. No operations were acquired or discontinued in the period.

The accompanying notes are an integral part of these financial statements.

 

condensed statement of changes in equity (unaudited)

Sharecapital£'000

Sharepremiumaccount£'000

Capitalreserve£'000

Capitalredemptionreserve£'000

Revenuereserve£'000

Total£'000

six months ended 31 July 2021

31 January 2021

701

1,301

737,228

169

2,831

742,230

Total comprehensive income for the period

-

-

138,818

-

(874)

137,944

Shares purchased for cancellation

(1)

-

(971)

1

-

(971)

31 July 2021

700

1,301

875,075

170

1,957

879,203

six months ended 31 July 2020

31 January 2020

708

1,301

612,022

162

6,530

620,723

Total comprehensive income for the period

-

-

(57,631)

-

(629)

(58,260)

31 July 2020

708

1,301

554,391

162

5,901

562,463

year ended 31 January 2021

31 January 2020

708

1,301

612,022

162

6,530

620,723

Total comprehensive income for the year

-

-

129,547

-

531

130,078

Dividend paid

-

-

-

-

(4,230)

(4,230)

Shares purchased for cancellation

(7)

-

(4,341)

7

-

(4,341)

31 January 2021

701

1,301

737,228

169

2,831

742,230

 

The accompanying notes are an integral part of these financial statements.

 

condensed balance sheet (unaudited)

As at31 July2021£'000

As at31 July2020£'000

As at31 January2021£'000

non current assets

Investments at fair value through profit or loss

866,653

538,785

712,874

866,653

538,785

712,874

current assets

Trade and other receivables

2,721

3,150

3,211

Cash and cash equivalents

10,397

21,044

33,918

13,118

24,194

37,129

total assets

879,771

562,979

750,003

current liabilities

Trade and other payables

(568)

(516)

(7,773)

total liabilities

(568)

(516)

(7,773)

total assets less current liabilities

879,203

562,463

742,230

net assets

879,203

562,463

742,230

represented by:

Share capital

700

708

701

Share premium account

1,301

1,301

1,301

Capital reserve

875,075

554,391

737,228

Capital redemption reserve

170

162

169

Revenue reserve

1,957

5,901

2,831

total equity attributable to equity holders of the company

879,203

562,463

742,230

net asset value per ordinary share (note 6):

Basic and diluted

6,280p

3,972p

5,292p

 

The accompanying notes are an integral part of these financial statements.

 

condensed cash flow statement (unaudited)

Six months ended31 July2021£'000

Six months ended31 July2020£'000

Year ended31 January2021£'000

cash flows from operating activities

Investment income received

3,201

2,592

6,202

Deposit interest received

-

1

4

Other income

5

-

-

Investment Manager's fees and performance fees paid

(7,586)

(3,892)

(7,082)

Transfer from subsidiary

-

95

104

Other cash payments

(1,544)

(599)

(923)

cash expended fromoperations (note 7)

(5,924)

(1,803)

(1,695)

Taxation paid

(12)

(18)

(15)

net cash outflow from

operating activities

(5,936)

(1,821)

(1,710)

cash flows from investing activities

Purchases of investments

(162,543)

(100,948)

(265,471)

Sales of investments

146,174

106,166

292,209

net cash (outflow)/inflow from investing activities

(16,369)

5,218

26,738

cash flows from financing activities

Dividend paid

-

-

(4,230)

Repurchase of Ordinary Shares for cancellation

(1,153)

-

(4,159)

net cash outflow from financing activities

(1,153)

-

(8,389)

(decrease)/increase in cash and cash equivalents for the period

(23,458)

3,397

16,639

cash and cash equivalents at the start of the period

33,918

17,805

17,805

Revaluation of foreign currency balances

(63)

(158)

(526)

cash and cash equivalents at the end of the period

10,397

21,044

33,918

 

The accompanying notes are an integral part of these financial statements.

 

notes to the financial statements (unaudited)

1. a) basis of accounting

North Atlantic Smaller Companies Investment Trust plc is a company incorporated and registered in England and Wales. The principal activity of the Company is that of an investment trust company within the meaning of Sections 1158/1159 of the Corporation Tax Act 2010.

The condensed financial statements of the Company have been prepared in accordance with International Accounting Standard ("IAS") 34 - "Interim Financial Reporting" in conformity with the requirement of the Companies Act 2006. The accounting policies and methods of computation followed in these half-yearly condensed financial statements are consistent with the most recent annual financial statements for the year ended 31 January 2021 included in the Annual Report.

The financial statements have also been prepared in accordance with the AIC SORP for the financial statements of investment trust companies and venture capital trusts, except to any extent where it is not consistent with the requirements of IFRS.

The financial information contained in this Half-Yearly Report does not constitute statutory accounts as defined in the Companies Act 2006. The financial information for the periods ended 31 July 2021 and 31 July 2020 have not been audited or reviewed by the Company's Auditor. The figure and financial information for the year ended 31 January 2021 are an extract from the latest published audited financial statements, which have been filed with the Registrar of Companies. The report of the Auditor on those financial statements was unqualified and did not contain a statement under either Section 498(2) or 498(3) of the Companies Act 2006.

b) functional currency

The functional currency of the Company is Pounds Sterling because this is the primary economic currency in which the Company operates. The financial statements are presented in Pounds Sterling rounded to the nearest thousand, except where otherwise indicated.

c) significant accounting policies

The accounting policies applied are consistent with those of the Annual Financial Report for the year ended 31 January 2021. Since the year end no new standards have been adopted.

d) accounting developments

In the current period, the Company has applied a number of amendments to IFRS, issued by the IASB mandatorily effective for an accounting period that begins on or after 1 January 2021. These include annual improvements to IFRS, changes in standards, legislative and regulatory amendments, changes in disclosure and presentation requirements. The adoption of these has not had any material impact on these condensed financial statements.

e) segmental reporting

The Directors are of the opinion that the Company is engaged in a single segment of business, being investment business. The Company invests in smaller companies principally based in countries bordering the North Atlantic Ocean.

f) going concern

The financial statements have been prepared on a going concern basis and on the basis that approval as an investment trust company will continue to be met. The Directors have made an assessment of the Company's ability to continue as a going concern and are satisfied that the Company has the resources to continue in business for the foreseeable future, being a period of 12 months from the date when these financial statements were approved. In making the assessment, the Directors have considered the likely impacts of the current COVID-19 pandemic on the Company, operations and the investment portfolio. The Directors noted the cash balance exceeds any short term liabilities; the Company holds a portfolio of liquid investments and is able to meet the obligations of the Company as they fall due. The surplus cash enables the Company to meet any funding requirements and finance future additional investments. The Company is a closed end fund, where assets are not required to be liquidated to meet day to day redemptions. The Directors have completed stress tests assessing the impact of changes in market value and income with associated cashflows. Whilst the economic future is uncertain, and the Directors believe it is possible the Company could experience further reductions in income and/or market value that this should not be to a level which would threaten the Company's ability to continue as a going concern. The Directors, the Manager and other service providers have put in place contingency plans to minimise disruption. Furthermore, the Directors are not aware of any material uncertainties that may cast significant doubt upon the Company's ability to continue as a going concern, having taken into account the liquidity of the Company's investment portfolio and the Company's financial position in respect of its cash flows, borrowing facilities and investment commitments (of which there are none of significance). Therefore, the financial statements have been prepared on the going concern basis.

2. investment management and performance fees

A Performance Fee is only payable if the investment portfolio, including Oryx at the adjusted price, outperforms the Sterling adjusted Standard & Poor's 500 Composite Index at the end of each financial year and is limited to a maximum payment of 0.5% of Shareholders' Funds, and is allocated 100% to capital.

An amount would be included in these financial statements for the Performance Fee that could be payable based on investment performance to 31 July 2021. At that date, no Performance Fee, exclusive of VAT, has been accrued for in the accounts (31 July 2020: £nil; 31 January 2021: £3,774,000).

Further details of fees paid to the investment manager can be found in Note 10, Related Party transactions.

3. taxation

The Company has an effective tax rate of 0%. The estimated effective tax rate is 0% as investment gains are exempt from tax owing to the Company's status as an Investment Trust and there is expected to be an excess of management expenses over taxable income and thus there is no charge for corporation tax.

During the half year to 31 July 2021, the Company recognised a total charge of £12,000 (half year to 31 July 2020: £18,000, year ended 31 January 2021: £15,000), representing irrecoverable withholding tax paid on overseas investment income.

4. dividends

For the year ended 31 January 2021, there was no final dividend proposed by the Board (31 January 2020; 30p per Ordinary Share).

 

5. earnings per ordinary share

 

Revenue

Capital

Total

Netreturn£'000

OrdinaryShares

PerSharepence

Netreturn£'000

OrdinaryShares

PerSharepence

Netreturn£'000

OrdinaryShares

PerSharepence

six months ended 31 July 2021

Basic and diluted return per Share

(874)

14,001,025

(6.2)

138,818

14,001,025

991.4

137,944

14,001,025

985.2

sixmonths ended 31 July 2020

Basic and diluted return per Share

(629)

14,160,000

(4.4)

(57,631)

14,160,000

(407.0)

(58,260)

14,160,000

(411.4)

year ended 31 January 2021

Basic and diluted return per Share

531

14,133,859

3.7

129,547

14,133,859

916.6

130,078

14,133,859

920.3

 

Basic return per Ordinary Share has been calculated using the weighted average number of Ordinary Shares in issue during the period.

6. net asset value per ordinary share

The net asset value per Ordinary Share is based on net assets of £879,203,000 (31 July 2020: £562,463,000; 31 January 2021: £742,230,000) and on 14,000,000 Ordinary Shares (31 July 2020: 14,160,000; 31 January 2021: 14,024,518) being the number of Ordinary Shares in issue at the period end.

During the period to 31 July 2021, 24,518 shares were bought back for cancellation at a total cost, including stamp duty, of £971,000.

adjustment for Oryx

The Company has also reported an adjusted net asset value per share using equity accounting, in accordance with its previous method of valuing its investment in Oryx. The Company has chosen to report this net asset value per share to show the difference derived if equity accounting were to be used. Equity accounting permits the use of net asset value pricing for listed assets which in the case of Oryx is higher than its fair value.

 

The values of Oryx, as at each period end, are as follows:

 

31 July 2021 £'000

31 July 2020 £'000

31 January 2021 £'000

Oryx at Fair value (traded price)

136,023

74,831

104,321

Oryx value using Equity Accounting

136,760

88,544

113,168

Increase in net assets using Equity Accounting

737

13,713

8,847

 

 

31 July 2021

31 July 2020

31 January 2021

Net asset value per Share

 

 

 

- Basic

6,280p

3,972p

5,292p

- Diluted

6,280p

3,972p

5,292p

 

 

 

 

Net asset value per Share adjusted

 

 

 

- Basic

6,285p

4,069p

5,355p

- Diluted

6,285p

4,069p

5,355p

 

7. reconciliation of total return before taxation to cash expended from operations

 

Six months

ended

31 July 2021

£'000

Six months

ended

31 July 2020

£'000

Year ended

31 January 2021

£'000

Total return before taxation

137,956

(58,242)

130,093

(Gains)/losses on investments

(138,818)

57,631

(133,316)

Interest reinvested

-

-

(1,901)

Transfer from Subsidiary

-

95

104

Increase in debtors and accrued income

(569)

(584)

(518)

(Decrease)/increase in creditors and accruals

(4,493)

(703)

3,843

 

 

 

 

Cash expended from operations

(5,924)

(1,803)

(1,695)

8. investments

financial assets at fair value through profit or loss

This requires the Company to classify fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy consists of the following three levels:

· Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

· Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices).

· Level 3 - Inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The level in the fair value hierarchy within which the fair value measurement is categorised in its entirety is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety.

For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Company. The Company considers observable data from investments actively traded in organised financial markets, fair value is generally determined by reference to Stock Exchange quoted market bid prices at the close of business on the Balance Sheet date, without adjustment for transaction costs necessary to realise the asset.

The table below sets out fair value measurements as at the period end, by the level in the fair value hierarchy into which the fair value measurement is categorised.

six months ended 31 July 2021

Total£'000

Level 1£'000

Level 2£'000

Level 3£'000

Equity investments at fair value

774,174

678,567

-

95,607

Fixed interest investments at fair value

92,479

61,476

-

31,003

Total

866,653

740,043

-

126,610

 

 

 

 

 

six months ended 31 July 2020

Total£'000

Level 1£'000

Level 2£'000

Level 3£'000

Equity investments at fair value 

451,559

380,890

-

70,669

Fixed interest investments at fair value

87,226

43,982

-

43,244

Total

538,785

424,872

-

113,913

 

 

 

 

 

year ended 31 January 2021

Total£'000

Level 1£'000

Level 2£'000

Level 3£'000

Equity investments at fair value

634,685

552,579

-

82,106

Fixed interest investments at fair value

78,189

54,615

-

23,574

Total

712,874

607,194

-

105,680

reconciliation of level 3 movement - financial assets at 31 July 2021

 

Total£'000

Equity investments£'000

Fixed interest investments£'000

Opening fair value at 31 January 2021

105,680

82,106

23,574

Purchases

16,867

10,732

6,135

Sales

(3,764)

(3,764)

-

Total gains included in gains on investments in the statement of comprehensive income:

 

 

 

- on assets sold

(146)

(146)

-

- on assets held at the end of the period

7,973

6,679

1,294

Closing fair value

126,610

95,607

31,003

unquoted at directors' estimate of fair value

Unquoted investments are valued in accordance with the International Private Equity and Venture Capital Valuation ("IPEV") Guidelines. Their valuation incorporates all factors that market participants would consider in setting a price. The primary valuation techniques employed to value the unquoted investments are earnings multiples, recent transactions and the net asset basis. Valuations in local currency are translated into Sterling at the exchange rate ruling on the Balance Sheet date.

Included within the Statement of Comprehensive Income as at 31 July 2021, is a gain of £7,973,000 relative to the movement in the fair value of the unquoted investments valued using IPEV valuation techniques.

the valuation techniques applied are based on the following assumptions:

Unquoted investments are usually valued by reference to the valuation multiples of similar listed companies or from transactions of similar businesses. Where appropriate discounts are then applied to those comparable multiples to reflect differences in size and liquidity. These enterprise values are then adjusted for net debt to arrive at an equity valuation. Where companies are in compliance with the loan note terms these loans are generally held at par plus accrued interest (where applicable) unless the enterprise value suggests that the debt cannot be recovered.

9. related party transactions

There have been no changes to the related party arrangements or transactions as reported in the Statutory Annual Financial Report for the year ended 31 January 2021.

The Administrator, Harwood Capital LLP, is regarded as a related party of the Company. The amounts incurred by Harwood Capital LLP and Growth Financial Services Limited in respect of investment management for the period are as follows:

 

Six months ended

31 July 2021

£'000

Six months ended

31 July 2020

£'000

Year ended

31 January 2021

£'000

Fees incurred by Harwood Capital LLP

2,253

1,914

3,828

Fees incurred by GFS

1,502

1,276

2,552

Performance fee

-

-

3,774

Irrecoverable VAT thereon

-

-

30

Irrecoverable VAT thereon - PYA

-

-

(35)

 

3,755

3,190

10,149

 

At 31 July 2021, £376,000 was payable to Harwood Capital in respect of outstanding management fees (31 July 2020: £319,000, 31 January 2021: £270,000). At 31 July 2021, there was no fee payable to GFS in respect of outstanding performance fees (31 July 2020: £nil, 31 January 2021: £501,000) net of VAT.

Fees paid to Directors, for the six months ended 31 July 2021 amounted to £65,000 (six months ended 31 July 2020: £65,000; year ended 31 January 2021: £130,000).

At 31 July 2021, £11,000 was payable to Directors in respect of outstanding fees (31 July 2020: £11,000, 31 January 2021 £11,000).

 

shareholder information

financial calendar

Announcement of results and annual report

May

Annual General Meeting

June

Half Yearly figures announced

September

Half Yearly Report posted

September

share price

The Company's mid-market share price is quoted daily in the Financial Times appearing under "Investment Companies".

It also appears on:

SEAQ Ordinary Shares: NASTrustnet: www.trustnet.com

net asset value

The latest net asset value of the Company can be found on the Company's website: www.nascit.co.uk

share dealing

Investors wishing to purchase more Ordinary Shares or dispose of all or part of their holding may do so through a stockbroker. Many banks also offer this service.

The Company's registrars are Link Group. In the event of any queries regarding your holding of shares, please contact the registrars on: 0871 664 0300, or by email on enquiries@linkgroup.co.uk

Changes of name or address must be notified to the registrars in writing at:

Link Group

10th Floor

Central Square

29 Wellington Street

Leeds LS1 4DL

Directors

Peregrine Moncreiffe (Chairman)

Christopher Mills (Chief Executive)

Lord Howard of Rising

G Walter Loewenbaum

Sir Charles Wake

Administrator

Harwood Capital LLP

(Authorised and regulated by the Financial Conduct Authority)

6 Stratton Street

Mayfair

London W1J 8LD

Telephone: 020 7640 3200

Financial Adviser and Stockbroker

Winterflood Investment Trusts

The Atrium Building

Cannon Bridge

25 Dowgate Hill

London EC4R 2GA

 

Registered Office

6 Stratton Street

Mayfair

London W1J 8LD

Telephone: 020 7640 3200

Registrars

Link Group

10th Floor

Central Square

29 Wellington Street

Leeds LS1 4DL

Auditors

RSM UK Audit LLP

25 Farringdon Street

London EC4A 4AB

Company Secretary

Derringtons Limited

Hyde Park House

5 Manfred Road

London SW15 2RS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR EQLFFFKLFBBD
Date   Source Headline
17th Apr 202410:52 amRNSNet Asset Value(s)
12th Apr 20243:48 pmRNSHolding(s) in Company
8th Apr 20249:42 amRNSTransaction in Own Shares
2nd Apr 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 202412:45 pmRNSTransaction in Own Shares - Replacement
21st Mar 20247:00 amRNSTransaction in Own Shares
20th Mar 20243:55 pmRNSNet Asset Value(s)
15th Mar 202410:01 amRNSHolding(s) in Company
27th Feb 20247:00 amRNSDirector/PDMR Shareholding
19th Feb 202411:07 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSDividend Declaration
15th Feb 20247:00 amRNSNet Asset Value(s)
8th Feb 20247:00 amRNSTransaction in Own Shares
5th Feb 20249:14 amRNSNew Investment: Crest Foods
5th Feb 20247:00 amRNSTransaction in Own Shares
31st Jan 20247:00 amRNSDirector/PDMR Shareholding
17th Jan 20243:32 pmRNSNet Asset Value(s)
27th Dec 20237:00 amRNSDirector Declaration
19th Dec 20237:00 amRNSNet Asset Value(s)
6th Dec 20237:41 amRNSInvestment Update: Ten Entertainment Group Plc
16th Nov 202312:44 pmRNSNet Asset Value(s)
30th Oct 20232:30 pmRNSTransaction in Own Shares
23rd Oct 20232:10 pmRNSTransaction in Own Shares
16th Oct 202312:19 pmRNSNet Asset Value(s)
12th Oct 20238:43 amRNSReplacement: Private Equity Investment Disposal
12th Oct 20237:00 amRNSPrivate Equity investment disposal
9th Oct 20233:02 pmRNSTransaction in Own Shares
15th Sep 20237:00 amRNSHalf-year Report
14th Sep 20231:43 pmRNSNet Asset Value(s)
31st Aug 20234:40 pmRNSCompany Secretary Change
29th Aug 20233:46 pmRNSTransaction in Own Shares - Replacement
29th Aug 20232:49 pmRNSTransaction in Own Shares
21st Aug 20233:07 pmRNSTransaction in Own Shares
16th Aug 20234:15 pmRNSTransaction in Own Shares
15th Aug 202310:03 amRNSNet Asset Value(s)
14th Aug 20232:09 pmRNSTransaction in Own Shares
8th Aug 20234:30 pmRNSTransaction in Own Shares
7th Aug 20234:28 pmRNSTransaction in Own Shares
25th Jul 202312:52 pmRNSNanoco Group Plc
18th Jul 20233:23 pmRNSNet Asset Value(s)
17th Jul 202312:41 pmRNSPortfolio Update
10th Jul 20239:39 amRNSTransaction in Own Shares
3rd Jul 202310:14 amRNSTransaction in Own Shares
30th Jun 202312:17 pmRNSDirector/PDMR Shareholding
26th Jun 202310:00 amRNSTransaction in Own Shares
21st Jun 20237:00 amRNSResult of AGM
15th Jun 20231:15 pmRNSNet Asset Value(s)
26th May 20235:10 pmRNSDirectorate Change
22nd May 20231:37 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.